drugset
drugset / Trial / NCT00312754

A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

NCT00312754 ↗

Phase 4 Terminated 70 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical research study is to learn if BMS-232632 administered as Atazanavir/ritonavir (ATV/RTV) is superior to an anti-retroviral regimen including Lopinavir/ritonavir (LPV/RTV), as assessed by an increased brachial artery flow-mediated vasodilatation (FMD), in HIV-infected patients. The safety of this treatment will also be studied.

Timeline

Start
2005-06
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified — —

Indications

HIV infectious disease